findmyKOL
Clinical trialNCT01239342TerminatedPhase 2Interventional

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

SponsorNational Cancer Institute (NCI)Enrollment43Metastatic Kidney CarcinomaRecurrent Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v7Stage IV Renal Cell Cancer AJCC v7
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Tower Cancer Research Foundation

    Beverly Hills, California, United States

  • City of Hope Comprehensive Cancer Center

    Duarte, California, United States

  • Usc / Norris Comprehensive Cancer Center

    Los Angeles, California, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, United States

  • City of Hope South Pasadena

    South Pasadena, California, United States

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania, United States

  • University of Pittsburgh Cancer Institute (upci)

    Pittsburgh, Pennsylvania, United States

  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Jan 2011
Primary completion
19 Sept 2018
Completion
19 Sept 2018
Last update posted
10 Oct 2019
Registered enrollment
43
Registry id
NCT01239342

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.